Clinical Trial Update: Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating nivolumab as immune checkpoint therapy for esophageal squamous cell carcinoma; the study status is terminated with results posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: NYU Langone Health | Conditions: Esophageal Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-03-28